Prostate Cancer International is
for 2011 by Great NonProfits
If you just read the media reports (for example, from Reuters, from the BBC or from The Daily Telegraph) you might get the idea that a new urine-based test for a protein called MSMB is vastly better at detecting prostate cancer than the PSA test. Sorry, but that is not actually the case at all.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: gene, microseminoprotein-β, MSMB, risk | 1 Comment »
There is an interesting new paper forthcoming in the Journal of Urology in which the research team describes how the addition of data from genetic profiling is able to improve the accuracy of the Kattan pre-treatment nomogram specifically in men believed to have localized prostate cancer at the time of diagnosis.
Filed under: Diagnosis, Management, Risk, Uncategorized | Tagged: gene, Kattan, nomogram, pre-treatment, prognosis | Leave a Comment »
Writing in the July issue of Genomic Medicine, Fredrik Wiklund (an expert on the genetics of prostate cancer) states that, “[R]ecent genome-wide association studies have revealed numerous genetic variants” associated with prostate cancer. He continues by stating,
Filed under: Diagnosis, Management, Prevention | Tagged: gene, genetics, risk | 4 Comments »
New data from a research team at the Institute for Cancer Research in the UK suggest that — in men and women with a faulty BRCA2 gene — the development of breast cancer and prostate cancer follows a similar pathway.
Filed under: Uncategorized | Tagged: BRCA2, gene | Leave a Comment »
According to a media release from the Prostate Cancer Foundation yesterday, research at the University of Michigan Comprehensive Cancer Center suggests that the RAF oncogene that drives fatal forms of melanoma (an aggressive type of skin cancer) may also drive aggressive forms of prostate cancer.
Filed under: Diagnosis, Drugs in development, Risk, Uncategorized | Tagged: fusion, gene, oncogene, RAF | 5 Comments »
An article in today’s Israel Herald might give you the (incorrect) idea that androgen deprivation therapy is completely inappropriate as a form of treatment for prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: development, fusion, gene | 1 Comment »
In a case that has major ramifications for the health care industry and for personalized medicine, a federal judge in New York yesterday invalidated the patents on BRAC1 and BRAC2 genes held by Myriad Genetics and the University of Utah.
Filed under: Diagnosis, Management, Prevention, Risk, Treatment | Tagged: gene, patent, test | 1 Comment »
Another new article in the Proceedings of the National Academy of Sciences has suggested the possibility of major progress in the prostate cancer research field — but at least this time the media seem to have got the story right!
Filed under: Diagnosis, Risk | Tagged: aggressive, association, gene, grade, indolent, variant | Leave a Comment »
Frankly … not that much … but a new “brief review” in BJU International provides a good summary of the little that we really do know about the variations between specific areas of human DNA (“gene polymorphism”) and the relationship of such genetic variation to risk for prostate cancer.
Filed under: Diagnosis, Risk | Tagged: gene, polymorphism, variation | Leave a Comment »
It may not be a cure for prostate cancer (or even a cure for any cancer) but scientists at the University of Rochester think they may have been able to work out why a rodent called the “naked mole rat” never gets cancer
Filed under: Uncategorized | Tagged: gene, mole rat, p16 | 3 Comments »
We have long cautioned about whether the presence of apparent biologic “markers” in men with prostate cancer (“association”) is necessarily an implication that a specific marker really indicates anything clinically important. A paper published by a European team now helps to put this in perspective.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: association, fusion, gene, marker, TMPRSS2-ERG | 5 Comments »
In today’s news reports we include items on: ETS gene fusions and their future in the diagnosis and management of prostate cancer Outcomes after different types of radiotherapy Micro-RNAs and late stage prostate cancer
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ETS, fusion, gene, micro RNA, outcome, radiation, therapy | Leave a Comment »
In today’s news reports there are items on: Genetic modifications and prostate cancer risk and development Situation-specific prostate biopsy strategies A viral vector-prodrug combination in treatment of local and locally advanced disease Docetaxel + 153Sm lexidronam in metastatic CRPC
Filed under: Diagnosis, Drugs in development, Management, Risk | Tagged: biopsy, CB1954, development, docetaxel, gene, risk, samarium-153 lexidronam, vector | Leave a Comment »
Today’s news reports cover items on: Gene expression and prostate cancer progression Risk of complications from in-office prostate biopsy Post-RALP voiding function Urinary toxicities after IMRT-SIB Drugs in development for CRPC
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: biopsy, CRPC, ERG, expression, gene, IMRT, PTEN, RALP, side effects, toxicity, urinary, voiding | Leave a Comment »
In today’s news reports we discuss: Genetic abnormalities and intermediate risk prostate cancer Ginger tablets to prevent chemotherapy-induced nausea Ixabebilone + mitoxantrone in patients after Taxotere
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: chemotherapy, expression, gene, ginger, intermediate, ixabepilone, mitoxantrone, nausea, risk | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site